Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Current Value
$9.931 Year Return
Current Value
$9.931 Year Return
Market Cap
$487.81M
P/E Ratio
-9.8
1Y Stock Return
-3.50%
1Y Revenue Growth
15.93%
Dividend Yield
0.00%
Price to Book
2.6
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TBI | 44.74% | $199.52M | -50.80% | 0.00% |
JMIA | 37.93% | $380.31M | +30.53% | 0.00% |
CHGG | 37.65% | $175.24M | -83.42% | 0.00% |
AHCO | 35.38% | $1.31B | +17.07% | 0.00% |
TRUE | 31.01% | $346.09M | +56.08% | 0.00% |
CVGI | 30.90% | $82.11M | -62.87% | 0.00% |
VPG | 30.52% | $279.20M | -30.23% | 0.00% |
CDXS | 30.13% | $345.86M | +121.35% | 0.00% |
MGTX | 29.49% | $467.36M | +9.12% | 0.00% |
DK | 29.45% | $1.14B | -34.04% | 5.64% |
ML | 28.64% | $922.62M | +146.62% | 0.00% |
ALNT | 28.06% | $419.62M | -4.92% | 0.36% |
TTEC | 27.83% | $204.76M | -76.19% | 1.39% |
ALTO | 27.68% | $106.54M | -39.83% | 0.00% |
MTW | 27.62% | $353.03M | -29.67% | 0.00% |
XPER | 27.11% | $378.82M | -19.06% | 0.00% |
WSBF | 26.97% | $295.44M | +27.51% | 3.93% |
RVNC | 26.59% | $394.43M | -47.99% | 0.00% |
GAIN | 26.56% | - | - | 6.45% |
SOFI | 26.52% | $15.65B | +114.58% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RDY | <0.01% | $11.97B | +5.10% | 3.31% |
TCTM | 0.01% | $8.10M | -42.99% | 0.00% |
OLLI | 0.01% | $5.48B | +15.97% | 0.00% |
CDNS | 0.02% | $82.18B | +10.81% | 0.00% |
GENI | 0.02% | $1.97B | +71.29% | 0.00% |
SPB | 0.05% | $2.53B | +37.09% | 1.89% |
GEV | 0.05% | $93.72B | +159.05% | 0.00% |
FCN | -0.06% | $7.10B | -10.74% | 0.00% |
TXMD | -0.08% | $14.99M | -53.32% | 0.00% |
UAL | 0.10% | $31.00B | +139.00% | 0.00% |
RL | 0.11% | $12.77B | +68.74% | 1.53% |
BEEM | 0.11% | $58.36M | -29.34% | 0.00% |
BTU | 0.11% | $3.23B | +14.05% | 1.13% |
TMUS | 0.11% | $270.63B | +56.92% | 0.83% |
THC | -0.12% | $14.58B | +131.72% | 0.00% |
OCX | -0.12% | $42.93M | -36.09% | 0.00% |
PNNT | 0.14% | - | - | 12.79% |
KDP | 0.15% | $42.76B | -1.22% | 2.77% |
ASR | 0.15% | $7.56B | +26.22% | 0.00% |
NOC | 0.15% | $71.54B | +4.23% | 1.60% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LUMN | -26.47% | $7.85B | +486.36% | 0.00% |
KVUE | -19.13% | $45.42B | +19.05% | 3.43% |
BAX | -19.07% | $16.60B | -8.91% | 3.57% |
YOU | -16.41% | $2.50B | +34.63% | 1.10% |
SOLV | -15.95% | $11.58B | -16.19% | 0.00% |
CCEC | -15.36% | $1.02B | +28.03% | 3.26% |
ELF | -12.63% | $6.86B | +8.95% | 0.00% |
BRBR | -10.66% | $9.47B | +50.71% | 0.00% |
VHC | -10.57% | $19.06M | -38.36% | 0.00% |
CHD | -10.46% | $27.18B | +19.50% | 1.03% |
OXBR | -10.28% | $19.05M | +178.18% | 0.00% |
STG | -10.10% | $35.67M | +7.92% | 0.00% |
BVS | -9.73% | $757.61M | +201.04% | 0.00% |
CLX | -9.56% | $20.81B | +20.66% | 2.88% |
SYRS | -9.50% | $7.43M | -90.46% | 0.00% |
EXPE | -9.11% | $22.72B | +30.70% | 0.00% |
FENG | -8.82% | $13.37M | +96.77% | 0.00% |
ABNB | -8.76% | $82.12B | +3.64% | 0.00% |
NCMI | -8.75% | $641.63M | +63.48% | 0.00% |
BSY | -8.70% | $14.13B | -11.17% | 0.49% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IWC | 32.46% | $933.99M | 0.6% |
PBE | 30.79% | $258.53M | 0.58% |
BSVO | 29.22% | $1.53B | 0.47% |
XBI | 29.22% | $6.58B | 0.35% |
IWN | 28.57% | $13.17B | 0.24% |
IWM | 28.30% | $75.73B | 0.19% |
VTWO | 27.91% | $12.38B | 0.1% |
SMDV | 27.79% | $754.57M | 0.4% |
TOTL | 27.78% | $3.31B | 0.55% |
XSVM | 27.76% | $853.92M | 0.37% |
DFAT | 27.50% | $11.16B | 0.28% |
SMMV | 27.16% | $321.07M | 0.2% |
XPH | 27.10% | $157.87M | 0.35% |
FYX | 27.00% | $959.00M | 0.6% |
ARKG | 26.94% | $1.13B | 0.75% |
DES | 26.90% | $2.13B | 0.38% |
GSSC | 26.79% | $529.86M | 0.2% |
IBB | 26.75% | $6.66B | 0.45% |
PRFZ | 26.71% | $2.65B | 0.39% |
XME | 26.56% | $1.86B | 0.35% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBMF | 0.03% | $1.02B | 0.85% |
BITO | 0.09% | $2.65B | 0.95% |
AMLP | 0.10% | $9.45B | 0.85% |
BTF | -0.18% | $51.69M | 1.24% |
WEAT | 0.28% | $120.27M | 0.28% |
XBIL | -0.34% | $637.70M | 0.15% |
CLOI | -0.34% | $715.40M | 0.4% |
BILZ | -0.40% | $563.02M | 0.14% |
BLCN | 0.46% | $70.20M | 0.68% |
UNG | -0.65% | $908.80M | 1.06% |
HDRO | -0.76% | $164.26M | 0.3% |
FFOG | 0.81% | $118.40M | 0.55% |
BOXX | 0.87% | $4.43B | 0.1949% |
XLP | 0.90% | $16.03B | 0.09% |
SEIX | 1.02% | $268.81M | 0.62% |
DEFI | -1.07% | $13.58M | 0.94% |
MNA | 1.12% | $220.85M | 0.77% |
DXJ | 1.20% | $3.71B | 0.48% |
HYEM | 1.40% | $408.28M | 0.4% |
DBA | -1.50% | $755.88M | 0.93% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -22.32% | $388.04M | 1.43% |
FLRN | -21.67% | $2.33B | 0.15% |
MSOS | -16.27% | $632.80M | 0.83% |
ICLO | -15.13% | $209.30M | 0.2% |
CNBS | -14.39% | $21.10M | 0.77% |
BSCO | -13.38% | $2.35B | 0.1% |
JUCY | -13.30% | $324.29M | 0.6% |
YOLO | -12.50% | $34.71M | 1.03% |
FLTR | -12.32% | $1.79B | 0.14% |
KRBN | -12.30% | $242.47M | 0.85% |
FLOT | -11.32% | $7.31B | 0.15% |
FBY | -10.96% | $127.69M | 0.99% |
CSHI | -10.82% | $482.85M | 0.38% |
TBLL | -10.75% | $1.92B | 0.08% |
USDU | -9.99% | $201.97M | 0.5% |
UUP | -9.30% | $309.25M | 0.77% |
IBMM | -9.27% | $391.28M | 0.18% |
KCCA | -9.21% | $220.51M | 0.87% |
THTA | -8.66% | $32.20M | 0.49% |
KMLM | -8.61% | $353.87M | 0.9% |
Yahoo
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST (8:15 am PST/4:15 pm GMT) and will be hosting in-person meetings with the investment community at the conference.
SeekingAlpha
Tracking Seth Klarman's Baupost Group Holdings - Q3 2024 Update
Yahoo
Theravance Biopharma ( NASDAQ:TBPH ) Third Quarter 2024 Results Key Financial Results Revenue: US$16.9m (up 7.5% from...
Yahoo
TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Yahoo
Theravance Biopharma Inc (TBPH) reports robust quarterly sales growth and outlines strategic plans to enhance shareholder value amidst market challenges.
Yahoo
Theravance Bio (TBPH) delivered earnings and revenue surprises of 40% and 4.71%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.